1.29

0.78% 0.01

Tango Therapeutics Inc (TNGX)

Overview News Price History Option Chain Financials Why TNGX Down? Discussions Forecast

Tango Therapeutics Inc stock is traded at $1.29, with a volume of 467.14K. It is up +0.78% in the last 24 hours and down -33.85% over the past month. Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.

Previous Close:

$1.28

Open:

$1.27

24h Volume:

467.14K

Relative Volume:

0.66

Market Cap:

$144.86M

Revenue:

$42.51M

Net Income/Loss:

$-116.49M

P/E Ratio:

-1.1518

EPS:

-1.12

Net Cash Flow:

$-120.82M

1W Performance:

-0.39%

1M Performance:

-33.85%

6M Performance:

-81.57%

1Y Performance:

-82.71%

1-Day Range:

$1.27

$1.33

1-Week Range:

$1.25

$1.44

52-Week Range:

$1.11

$12.02

Tango Therapeutics Inc Stock (TNGX) Company Profile

Name

Tango Therapeutics Inc

Sector

Healthcare (1151)

Industry

Biotechnology (660)

Phone

(857) 320-4900

Address

201 BROOKLINE AVENUE, BOSTON

Employee

155

Twitter

Next Earnings Date

2024-11-06

Latest SEC Filings

TNGX's Discussions on Twitter

Compare TNGX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TNGX Tango Therapeutics Inc	1.29	144.86M	42.51M	-116.49M	-120.82M	-1.12
VRTX Vertex Pharmaceuticals Inc	489.10	127.47B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	563.16	62.43B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	596.20	37.03B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	234.56	31.06B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	230.98	26.16B	3.81B	-644.79M	-669.77M	-6.24

Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-17-24	Initiated	Jefferies	Buy
Apr-04-24	Initiated	Cantor Fitzgerald	Overweight
Feb-12-24	Initiated	Piper Sandler	Overweight
Dec-08-23	Initiated	B. Riley Securities	Buy
Oct-20-22	Upgrade	H.C. Wainwright	Neutral → Buy
Sep-20-21	Initiated	SVB Leerink	Outperform

View All

Tango Therapeutics Inc Stock (TNGX) Latest News

Apr 18, 2025

Tango Therapeutics, Inc. (NASDAQ:TNGX) Shares Acquired by Franklin Resources Inc. - Defense World

Apr 18, 2025

Apr 17, 2025

Tango Therapeutics, Inc. (NASDAQ:TNGX) Receives $12.33 Average PT from Analysts - Defense World

Apr 17, 2025

Tango Therapeutics’ (TNGX) Buy Rating Reaffirmed at HC Wainwright - Defense World

Apr 15, 2025

Apr 14, 2025

Tango Therapeutics stock holds Buy rating, $13 target from H.C. Wainwright - Investing.com Canada

Apr 14, 2025

Tango Therapeutics stock holds Buy rating, $13 target from H.C. Wainwright By Investing.com - Investing.com South Africa

Apr 14, 2025

Little Excitement Around Tango Therapeutics, Inc.'s (NASDAQ:TNGX) Revenues As Shares Take 28% Pounding - simplywall.st

Apr 14, 2025

American Century Companies Inc. Purchases 12,162 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World

Apr 14, 2025

Apr 09, 2025

Barbara Weber, M.D., Elected to ITM Supervisory Board - Yahoo

Apr 09, 2025

Reviewing Biomea Fusion (NASDAQ:BMEA) and Tango Therapeutics (NASDAQ:TNGX) - Defense World

Apr 09, 2025

Apr 07, 2025

Tango Therapeutics cuts nearly one-fifth of staff - BioPharma Dive

Apr 07, 2025

Apr 03, 2025

TNGX’s Wild Ride: Down -55.66% – What’s Next for TNGX? - investchronicle.com

Apr 03, 2025

Mar 31, 2025

Swiss National Bank Raises Stock Holdings in Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World

Mar 31, 2025

Mar 30, 2025

Charles Schwab Investment Management Inc. Acquires 26,192 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World

Mar 30, 2025

Mar 29, 2025

Bank of New York Mellon Corp Sells 8,715 Shares of Tango Therapeutics, Inc. (NASDAQ:TNGX) - Defense World

Mar 29, 2025

Mar 25, 2025

Tango Therapeutics to Highlight Preclinical Data on - GlobeNewswire

Mar 25, 2025

Breakthrough: Novel Brain-Penetrant Cancer Drugs Target Previously Untreatable Tumors - Stock Titan

Mar 25, 2025

Mar 24, 2025

Tango Therapeutics’ SWOT analysis: prmt5 inhibitor stock shows promise amid clinical trials By Investing.com - Investing.com South Africa

Mar 24, 2025

Tango Therapeutics’ SWOT analysis: prmt5 inhibitor stock shows promise amid clinical trials - Investing.com

Mar 24, 2025

Mar 21, 2025

Tango Therapeutics, Inc. (NASDAQ:TNGX) Short Interest Up 18.5% in February - Defense World

Mar 21, 2025

Mar 13, 2025

Tango Therapeutics executive sells shares worth $43,865 - MSN

Mar 13, 2025

Cantor Fitzgerald Issues Negative Forecast for TNGX Earnings - Defense World

Mar 13, 2025

Mar 10, 2025

Tango Therapeutics (TNGX) Expected to Announce Earnings on Monday - Defense World

Mar 10, 2025

Mar 07, 2025

Tango Therapeutics Shuts Early-Stage Cancer Study Due To Liver Toxicity - MSN

Mar 07, 2025

Mar 06, 2025

Mesothelioma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail

Mar 06, 2025

Feb 28, 2025

Tango Therapeutics (NASDAQ:TNGX) Issues Earnings Results - MarketBeat

Feb 28, 2025

Tango Therapeutics, Inc. (NASDAQ:TNGX) Looks Inexpensive After Falling 30% But Perhaps Not Attractive Enough - Simply Wall St

Feb 28, 2025

Tango Therapeutics Full Year 2024 Earnings: Revenues Disappoint - Yahoo Finance UK

Feb 28, 2025

Tango Therapeutics Advances Cancer Treatment Pipeline - TipRanks

Feb 28, 2025

Feb 27, 2025

Tango Therapeutics earnings missed, revenue fell short of estimates By Investing.com - Investing.com Canada

Feb 27, 2025